Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alemtuzumab + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Cellectis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
A combination therapy consisting of alemtuzumab, a humanized monoclonal antibody targeting CD52, and cyclophosphamide, an alkylating chemotherapeutic agent. This combination is primarily used in the treatment of hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and T-cell lymphomas. The combination works through complementary mechanisms: alemtuzumab binds to CD52 on lymphocytes, causing antibody-dependent cellular cytolysis and complement-mediated lysis, while cyclophosphamide interferes with DNA replication and RNA transcription to prevent cell division.
- Brand names
- Campath
- Other names
- cyclophosphamide + Campath IHcyclophosphamide + alemtuzumab
02
Targets
CD52 (CD52 Antigen)DNA
Beyond the preview
Go deeper on alemtuzumab + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alemtuzumab + cyclophosphamide.